[Form 4] CVS HEALTH Corp Insider Trading Activity

Rhea-AI Filing Summary

CVS Health Corp executive Tilak Mandadi, EVP and Chief Experience & Technology Officer, reported an automatic share disposition related to equity compensation. On 11/30/2025, he disposed of 6,575 shares of CVS common stock at $80.36 per share. The filing explains this was a surrender of shares to pay withholding taxes due upon the vesting and settlement of a restricted stock unit award, which is a common administrative transaction rather than an open‑market sale. After this tax-related transaction, Mandadi beneficially owned 74,085 CVS shares, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mandadi Tilak

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RI 02895

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Exp & Tech Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/30/2025		F(1)		6,575	D	$80.36	74,085	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Surrender of shares in payment of withholding taxes due upon the vesting and settlement of a restricted stock unit award.

	/s/ Tilak Mandadi	12/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CVS (CVS) report for Tilak Mandadi?

CVS disclosed that EVP and Chief Experience & Technology Officer Tilak Mandadi disposed of 6,575 CVS common shares on 11/30/2025 in connection with equity compensation.

At what price were Tilak Mandadis CVS (CVS) shares disposed of?

The 6,575 CVS shares associated with the transaction were valued at $80.36 per share according to the reported price in the filing.

Why did the CVS (CVS) executive surrender 6,575 shares?

The filing states the 6,575 shares were surrendered to pay withholding taxes due upon the vesting and settlement of a restricted stock unit award, rather than as a discretionary market sale.

How many CVS (CVS) shares does Tilak Mandadi own after the transaction?

Following the reported transaction, Tilak Mandadi beneficially owned 74,085 CVS common shares, held in direct ownership.

What is Tilak Mandadis role at CVS Health Corp (CVS)?

Tilak Mandadi is an officer of CVS Health Corp, serving as EVP, Chief Experience & Technology Officer, as indicated in the filing.

Is the CVS (CVS) Form 4 transaction an open-market sale?

No. The explanation clarifies the transaction was a surrender of shares to cover withholding taxes upon RSU vesting, which differs from a voluntary open-market sale.